A pivot towards reselling Chinese-made coronavirus antibody tests in the U.S. has transformed tiny Aytu Bioscience (AYTU) into an overnight Covid-19 success story, with a soaring share price to match.

But the retail-investor frenzy behind the company’s unprecedented surge since early March disregards numerous risks and red flags. Any or all of them could send its stock price crashing lower. The Covid-19 pandemic has been devastating, but it will end — and so will the stock market bubble in micro-cap companies like Aytu.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy